The Alaunos Velaris Therapeutics acquisition turns a small public company into the vehicle for a new pulmonary hypertension drug developer backed by $350 million. On 13 October 2026, Alaunos Therapeutics announced that it had completed the acquisition of Velaris Therapeutics, a private company based in Waltham, Massachusetts, and had closed a concurrent private placement of about $350 million led by the investment firm Fairmount.
The money is large, but the science is early: none of Velaris’s drug candidates has entered human trials. Below we explain the deal, the drugs, the timetable the company has set and the caveats.
Key takeaways
- Alaunos completed its acquisition of Velaris and raised about $350 million in a private placement led by Fairmount.
- The company says the funding supports operations into 2029.
- Velaris’s lead programme, VLR199, is designed to match the action of the approved pulmonary arterial hypertension drug Winrevair.
- Proof-of-concept data are expected in 2028; first regulatory filings to begin trials are planned from the second half of 2027.
- No Velaris drug has been tested in people.
Details of the Alaunos Velaris Therapeutics acquisition
According to the company, Velaris equity holders received Alaunos common stock and a new class of non-voting convertible preferred stock. The $350 million placement was of the same non-voting Series C preferred stock, sold to institutional investors. Fairmount led it, and participants included Venrock Healthcare Capital Partners, accounts advised by T. Rowe Price, Wellington Management, Janus Henderson, Access Biotechnology, BB Biotech, Perceptive Advisors, Sirenia Capital and ADAR1 Capital.
Both boards and Velaris’s stockholders approved the transaction, and the closing did not need approval from Alaunos stockholders. Alaunos plans a stockholder meeting to approve converting the preferred stock into common stock. After that, three current directors will resign and three Fairmount designees will join the board, including Peter Harwin, a Fairmount founding partner. Velaris is the ninth company launched from assets discovered by Paragon Labs, which Fairmount founded.
Why pulmonary hypertension drives the Alaunos Velaris Therapeutics acquisition
Pulmonary arterial hypertension (PAH) is a rare, serious condition in which the small arteries of the lungs narrow and thicken, raising pressure and straining the right side of the heart. The National Heart, Lung, and Blood Institute describes pulmonary hypertension as a condition that can cause shortness of breath and fatigue and can become life-threatening. The Pulmonary Hypertension Association provides patient information.
Velaris’s thesis rests on a class of drugs that block activin signalling. The company says there is only one approved drug of this type for PAH, and that it aims to improve on areas where that therapy is not fully optimised. Its investor presentation names Winrevair (sotatercept) as the benchmark and cites estimated peak sales above $8 billion, a figure that is the company’s own projection and not a reported result.
The Velaris pipeline
- VLR199: an ActRIIA-Fc ligand trap, the lead programme, designed to replicate the pharmacology of the approved drug while improving on it.
- VLR247 and VLR258: ActRII-Fc ligand traps built to spare BMP-9 and BMP-10, which the company links to blood-related side effects.
- VLR360: an anti-PDGF-B antibody that targets a separate pathway and could be used alone or with the other drugs.
The company also points to possible use in secondary forms of pulmonary hypertension, including those linked to heart failure with preserved ejection fraction and interstitial lung disease. All of these are plans for animal and laboratory-stage drugs.
Timeline in the Alaunos Velaris Therapeutics acquisition plan
The investor presentation filed with the US Securities and Exchange Commission sets out the company’s intended milestones. It lists applications to begin clinical trials (an IND in the US or CTA in Europe) for VLR199 and VLR360 in the second half of 2027, and for VLR247 in the first half of 2028. It describes a small first study in about 20 to 30 healthy volunteers, followed by studies in PAH patients, with clinical initiation in 2027 and proof-of-concept data expected in 2028. These are targets, and drug development timelines often slip.
What happens to Alaunos’s older programme?
Alaunos, headquartered in Fort Lauderdale, Florida, also has an obesity and metabolic programme, ALN1003, an oral small-molecule candidate. The company says the new funding may also support that preclinical work. For other obesity-related deals, see our report on Ribo’s EU trial application for an obesity siRNA and our report on Roche’s Rona Therapeutics obesity deal, or browse our biotechnology coverage.
Our assessment of the Alaunos Velaris Therapeutics acquisition
In our assessment, the Alaunos Velaris Therapeutics acquisition is mainly a financing event for an early-stage company, built by specialist investors who have done similar deals before. A $350 million round is a strong vote of confidence and gives the company roughly three years to reach proof of concept. But a follow-on to an approved drug must show it is better, not just similar, and that is difficult without human data. The pipeline’s ambition, with several shots on goal, spreads risk but also spreads resources. We would wait for the first clinical results before drawing conclusions.
What to watch after the Alaunos Velaris Therapeutics acquisition
- The Alaunos stockholder meeting on converting the preferred stock.
- Board changes and any new company name or ticker.
- Regulatory filings for the first trials, planned from the second half of 2027.
- Early human safety data for VLR199.
Frequently asked questions about the Alaunos Velaris Therapeutics acquisition
What happened in the Alaunos Velaris Therapeutics acquisition?
Alaunos completed its acquisition of Velaris in a stock transaction and closed a concurrent private placement of about $350 million.
Who led the financing in the Alaunos Velaris Therapeutics acquisition?
Fairmount led the placement, joined by several institutional investors.
What does Velaris develop?
Drugs for pulmonary arterial hypertension and other forms of pulmonary hypertension, led by VLR199, which acts on activin signalling.
Are any Velaris drugs in clinical trials?
No. The company plans regulatory filings from the second half of 2027.
How long will the Alaunos Velaris Therapeutics acquisition money last?
The company says the funding supports operations into 2029.
How we reported this: we relied on Alaunos Therapeutics’ 13 October 2026 announcement and investor presentation filed with the SEC. These are company statements, and the projections are the company’s. Last updated: 14 October 2026. This article is news reporting and not investment or medical advice.
